Isolated Contralateral Axillary Lymph Node Involvement in Breast Cancer Represents a Locally Advanced Disease Not Distant Metastases

Rati Chkheidze, Mary Ann G. Sanders, Barbara Haley, A. Marilyn Leitch, Sunati Sahoo

Research output: Contribution to journalArticle

Abstract

A retrospective review was conducted to determine if isolated contralateral axillary lymph node metastasis in breast cancer patients represents a systemic spread or a locoregional spread. Our finding and the review of the literature indicate that patients with isolated contralateral axillary lymph node metastasis should be classified as N3 in the TNM system rather than M1 for appropriate staging and treatment. Background: Breast cancer metastases to an ipsilateral supraclavicular lymph node is assigned a N3 status in the TNM system and thus classified as stage III disease in the American Joint Commission on Cancer staging manual. Breast cancer metastatic to contralateral axillary lymph node (CAM) without metastases to any other distant organ is currently assigned M1 status (stage IV) instead of N3 (stage III). Patients and Methods: We retrospectively reviewed the medical records of breast cancer patients diagnosed with CAM for their clinical presentation, pathologic diagnoses, treatment, and follow-up data. Patients who had distant metastases at the time of CAM diagnosis were excluded from the study. Results: We report 12 breast cancer patients who developed CAM but no evidence of metastases in any other distant organ documented with extensive imaging workup. Imaging studies and thorough pathologic evaluation of the prophylactic total mastectomy specimen did not reveal a primary in the breast to account for the metastases in the axillary node. Conclusion: Findings of our study as well as previous studies support that lymph node metastases in the contralateral axilla represents a locoregional spread of the tumor from the index breast via lymphatics rather than hematogenous spread. Therefore, isolated CAM in breast cancer patients should not be classified as stage IV disease.

Original languageEnglish (US)
JournalClinical Breast Cancer
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Lymph Nodes
Breast Neoplasms
Neoplasm Metastasis
Simple Mastectomy
Axilla
Neoplasm Staging
Medical Records
Breast
Joints
Therapeutics

Keywords

  • Breast cancer staging
  • Breast carcinoma
  • Contralateral axillary lymph node metastasis
  • Cross over metastasis
  • Locally advanced breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{57333dd57bea46f79f8d4caaa181e550,
title = "Isolated Contralateral Axillary Lymph Node Involvement in Breast Cancer Represents a Locally Advanced Disease Not Distant Metastases",
abstract = "A retrospective review was conducted to determine if isolated contralateral axillary lymph node metastasis in breast cancer patients represents a systemic spread or a locoregional spread. Our finding and the review of the literature indicate that patients with isolated contralateral axillary lymph node metastasis should be classified as N3 in the TNM system rather than M1 for appropriate staging and treatment. Background: Breast cancer metastases to an ipsilateral supraclavicular lymph node is assigned a N3 status in the TNM system and thus classified as stage III disease in the American Joint Commission on Cancer staging manual. Breast cancer metastatic to contralateral axillary lymph node (CAM) without metastases to any other distant organ is currently assigned M1 status (stage IV) instead of N3 (stage III). Patients and Methods: We retrospectively reviewed the medical records of breast cancer patients diagnosed with CAM for their clinical presentation, pathologic diagnoses, treatment, and follow-up data. Patients who had distant metastases at the time of CAM diagnosis were excluded from the study. Results: We report 12 breast cancer patients who developed CAM but no evidence of metastases in any other distant organ documented with extensive imaging workup. Imaging studies and thorough pathologic evaluation of the prophylactic total mastectomy specimen did not reveal a primary in the breast to account for the metastases in the axillary node. Conclusion: Findings of our study as well as previous studies support that lymph node metastases in the contralateral axilla represents a locoregional spread of the tumor from the index breast via lymphatics rather than hematogenous spread. Therefore, isolated CAM in breast cancer patients should not be classified as stage IV disease.",
keywords = "Breast cancer staging, Breast carcinoma, Contralateral axillary lymph node metastasis, Cross over metastasis, Locally advanced breast cancer",
author = "Rati Chkheidze and Sanders, {Mary Ann G.} and Barbara Haley and Leitch, {A. Marilyn} and Sunati Sahoo",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.clbc.2017.10.019",
language = "English (US)",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",

}

TY - JOUR

T1 - Isolated Contralateral Axillary Lymph Node Involvement in Breast Cancer Represents a Locally Advanced Disease Not Distant Metastases

AU - Chkheidze, Rati

AU - Sanders, Mary Ann G.

AU - Haley, Barbara

AU - Leitch, A. Marilyn

AU - Sahoo, Sunati

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A retrospective review was conducted to determine if isolated contralateral axillary lymph node metastasis in breast cancer patients represents a systemic spread or a locoregional spread. Our finding and the review of the literature indicate that patients with isolated contralateral axillary lymph node metastasis should be classified as N3 in the TNM system rather than M1 for appropriate staging and treatment. Background: Breast cancer metastases to an ipsilateral supraclavicular lymph node is assigned a N3 status in the TNM system and thus classified as stage III disease in the American Joint Commission on Cancer staging manual. Breast cancer metastatic to contralateral axillary lymph node (CAM) without metastases to any other distant organ is currently assigned M1 status (stage IV) instead of N3 (stage III). Patients and Methods: We retrospectively reviewed the medical records of breast cancer patients diagnosed with CAM for their clinical presentation, pathologic diagnoses, treatment, and follow-up data. Patients who had distant metastases at the time of CAM diagnosis were excluded from the study. Results: We report 12 breast cancer patients who developed CAM but no evidence of metastases in any other distant organ documented with extensive imaging workup. Imaging studies and thorough pathologic evaluation of the prophylactic total mastectomy specimen did not reveal a primary in the breast to account for the metastases in the axillary node. Conclusion: Findings of our study as well as previous studies support that lymph node metastases in the contralateral axilla represents a locoregional spread of the tumor from the index breast via lymphatics rather than hematogenous spread. Therefore, isolated CAM in breast cancer patients should not be classified as stage IV disease.

AB - A retrospective review was conducted to determine if isolated contralateral axillary lymph node metastasis in breast cancer patients represents a systemic spread or a locoregional spread. Our finding and the review of the literature indicate that patients with isolated contralateral axillary lymph node metastasis should be classified as N3 in the TNM system rather than M1 for appropriate staging and treatment. Background: Breast cancer metastases to an ipsilateral supraclavicular lymph node is assigned a N3 status in the TNM system and thus classified as stage III disease in the American Joint Commission on Cancer staging manual. Breast cancer metastatic to contralateral axillary lymph node (CAM) without metastases to any other distant organ is currently assigned M1 status (stage IV) instead of N3 (stage III). Patients and Methods: We retrospectively reviewed the medical records of breast cancer patients diagnosed with CAM for their clinical presentation, pathologic diagnoses, treatment, and follow-up data. Patients who had distant metastases at the time of CAM diagnosis were excluded from the study. Results: We report 12 breast cancer patients who developed CAM but no evidence of metastases in any other distant organ documented with extensive imaging workup. Imaging studies and thorough pathologic evaluation of the prophylactic total mastectomy specimen did not reveal a primary in the breast to account for the metastases in the axillary node. Conclusion: Findings of our study as well as previous studies support that lymph node metastases in the contralateral axilla represents a locoregional spread of the tumor from the index breast via lymphatics rather than hematogenous spread. Therefore, isolated CAM in breast cancer patients should not be classified as stage IV disease.

KW - Breast cancer staging

KW - Breast carcinoma

KW - Contralateral axillary lymph node metastasis

KW - Cross over metastasis

KW - Locally advanced breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85044676318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044676318&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2017.10.019

DO - 10.1016/j.clbc.2017.10.019

M3 - Article

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

ER -